Core Viewpoint - Guizhou Moutai is undergoing a significant transformation in its corporate style and marketing strategy amidst a challenging market environment, as evidenced by changes in its annual shareholder meeting and budget plans [1][2][4]. Financial Performance - In 2024, Guizhou Moutai achieved total revenue of 174.144 billion yuan, a year-on-year increase of 15.66%, and a net profit of 86.228 billion yuan, up 15.38%, maintaining double-digit growth in key economic indicators [2]. - The company set a revenue growth target of 9% for 2025, indicating a shift from high-speed growth to high-quality development [4][6]. Strategic Adjustments - The company is focusing on self-regulation and adaptability, having successfully navigated several market adjustments in the past [2]. - Moutai is shifting its marketing strategy to emphasize consumer-centric approaches, addressing supply-demand mismatches, and enhancing service systems [4][6]. Budget and Expenses - The 2025 budget plan includes a significant increase in expenses, projected to grow by approximately 27%, primarily to strengthen domestic and international market development and increase advertising and market investments [6][7]. - In contrast, the 2024 budget had a more restrained expense growth of 13%, with actual expenses increasing by only 7.51% [6]. Market Dynamics - The current market environment for the liquor industry is characterized by a cooling consumer demand, prompting Moutai to control supply and stabilize prices while expanding its product offerings [4][5][7]. - The recent implementation of new regulations limiting high-end dining and alcohol consumption in government settings may further tighten the market, but the impact is expected to be limited [5]. International Expansion - Guizhou Moutai is actively pursuing international market opportunities, with overseas revenue reaching 1.119 billion yuan in Q1, a year-on-year increase of 37.53%, and total overseas revenue surpassing 5 billion yuan last year [7][8]. - The company's international strategy is structured in three phases: exporting products, promoting brand and culture, and achieving international value creation capabilities [8].

Core Viewpoint - Koyuan Pharmaceutical is actively enhancing its market position through strategic acquisitions and international expansion efforts, aiming to build a competitive healthcare platform and increase profitability for shareholders [2][3][4]. Group 1: Stock Performance and Investor Engagement - On May 19, Koyuan Pharmaceutical's stock rose by 5.63%, closing at 32.62 CNY per share, with a trading volume of 5,707,140 shares and a turnover of 184,453,540 CNY, indicating high market activity [1]. - The company participated in an investor reception event organized by the Shandong Securities Regulatory Bureau, discussing its 2024 performance, governance, development strategy, and sustainability with investors [1]. Group 2: Acquisition of Hongjitang - Koyuan Pharmaceutical announced the acquisition of 99.42% of Hongjitang, aiming to integrate high-quality traditional Chinese medicine assets and create a competitive healthcare platform [2]. - The acquisition is expected to enhance the company's net profit attributable to shareholders, thereby maximizing shareholder value [2]. - Hongjitang, established in 1907 and recognized as a "Chinese Time-honored Brand," holds 150 drug licenses and has leading market shares in key products like Ejiao and Angong Niuhuang Wan [2]. Group 3: Global Expansion and Product Development - Koyuan Pharmaceutical focuses on the research, production, and sales of chemical raw materials and formulations, striving to become a leading domestic and internationally competitive pharmaceutical manufacturer [3]. - The company invested 37.63 million CNY in R&D in 2024, accounting for 8.12% of its revenue, with a 24.56% year-on-year increase in R&D personnel [3]. - The product portfolio includes various categories such as antidiabetic, anesthetic, cardiovascular, and psychiatric drugs, with all products certified by national GMP and several international regulatory bodies [3]. Group 4: International Market Development - Koyuan Pharmaceutical showcased its key products and solutions at two major international exhibitions, CPhI Japan and in-cosmetics Global in the Netherlands, to enhance global visibility and foster international collaborations [4]. - The company has made significant strides in its internationalization strategy, establishing a comprehensive marketing network across Europe, the Americas, and Asia-Pacific, and enhancing its core competitiveness and global influence [4].

Core Viewpoint - The annual shareholder meeting of Guizhou Moutai highlighted the company's commitment to quality, culture, and adaptability in the face of changing market conditions and consumer behaviors [2][4][5]. Group 1: Company Strategy and Market Adaptation - Guizhou Moutai's chairman, Zhang Deqin, emphasized the importance of returning to the essence of Chinese liquor, focusing on quality and cultural significance [4]. - The company has successfully navigated multiple industry cycles, adapting its strategies during crises, which has led to significant brand and marketing advancements [5][6]. - The company aims to maintain confidence and resilience through its established brand value and quality, while executing strategic initiatives effectively [6]. Group 2: Transformation and Future Plans - Moutai's 2024 strategy includes three transformations: customer segmentation, scenario adaptation, and service enhancement, which have already shown positive results in recent sales data [6][7]. - The long-term goal is to build a more resilient ecosystem by understanding and balancing the interests of all stakeholders involved [7]. - The internationalization strategy focuses on a three-step approach, expanding from product exports to a comprehensive global brand presence [7]. Group 3: Pricing Strategy - The pricing of Moutai products will follow market principles, considering various factors such as market conditions, channel management, and stakeholder demands [8][9]. - The company is committed to maintaining a stable pricing structure across its product pyramid, which includes various product sizes and premium offerings [9].

Group 1: Report Overview - Reported company: Muyuan Foods Co., Ltd. [16] - Industry: Agriculture, Animal Husbandry, Feed, and Fishery [2] - Research date: May 16, 2025 [16] Group 2: Research Participants - Institutions and individuals participating in the research: Hu Peng, Dai Xuesong, Bai Xue, Bao Haibin, Zhang Tao, Liu Youzhi, Zhang Erkuan, etc. [19] Group 3: Chairman's Speech - Past decade achievements: The company has continuously improved in business, internal governance, and compliance, with shareholders' support, improved internal governance and successor systems, and emphasized compliance and social responsibility [23] - Accumulated capabilities: Product, service, industrial chain comprehensive development, and modern technology application capabilities [24] - Future plans: Strengthen pig - raising production capabilities to create greater value [25] Group 4: Cost Reduction and Future Outlook - Current cost: In April 2025, the full - cost of pig farming reached 12.4 yuan/kg, with a target of 12 yuan/kg this year, and excellent field lines can control it below 11 yuan/kg [26] - Cost reduction paths: Improve disease prevention and control, build a scientific breeding system, promote low - soybean diet technology, and apply intelligent equipment [26] - Value - added goals: Achieve a 600 - yuan cost reduction and 100 - yuan value - added per pig through an integrated industrial chain and consumer - oriented breeding [27] Group 5: Intelligent Application - Personnel training: Intelligent application is integrated into corporate culture and management, promoting experience sharing [28] - Health management: Intelligent pig houses maintain suitable temperatures, improving production indicators and reducing labor dependence [30] - Feed nutrition: Intelligent application enables precise feed formulation and reduces labor intensity [30] - Breeding: Build a high - value breeding platform to improve breeding efficiency and pig performance [30] Group 6: Slaughter and Meat Business - Business improvement: In Q1 2025, the slaughter and meat business improved significantly, and will increase investment in segmentation and R & D to meet consumer needs [31] Group 7: International Development - Motivation: Inspired by the Party's speech, aiming to share experience globally and promote the global pig - raising industry [32][33] - Plans: Cultivate international talents, pursue capital internationalization through a Hong Kong listing, and is in the early stage of internationalization [33][34] Group 8: Investor Return - Foundation: Stable operation and continuous profit are the basis for investor returns [36] - Dividend policy: Adjusted the cash - dividend ratio from 20% to 40% in 2024 - 2026, with a record - high dividend of 7.588 billion yuan in 2024 [36] - Market value management: Developed a market value management system and will adapt return plans to the company's development [36] Group 9: Debt and Capital Expenditure - Debt reduction: The asset - liability ratio has been decreasing since early 2024, and the company aims to reduce the debt by about 10 billion this year [37] - Capital expenditure: This year's capital expenditure is about 9 billion, and future expenditure will be further controlled [37]

5月18日，君乐宝旗下高端鲜奶悦鲜活在香港维多利亚港K11Musea举行"入港销售暨国际化战略发布 会"，宣布正式启动国际化战略。这意味着君乐宝在市场开拓及品牌提升上打开了新的空间。 科技创新支撑国际市场拓展根基 在低温鲜奶领域，杀菌技术与保质期的矛盾曾是长期困扰行业的难题。 2019年，君乐宝推出了悦鲜活品牌，其独创的INF0.09秒超瞬时杀菌技术很好地解决了以上的难题。该 技术在0.09秒内完成蒸汽浸入式杀菌，将牛奶中的乳铁蛋白、β-乳球蛋白等活性成分保留率提升至95% 以上，同时将保质期延长至19天。悦鲜活的长保质期使其能突破200公里冷链半径，实现了从"区域 鲜"到"全国鲜"的跨越。这助力了君乐宝在高端鲜奶领域的快速发展，尼尔森数据显示，悦鲜活在高端 鲜奶的市场占有率已达37.3%，在高端瓶装鲜奶的市场占有率更是高达49%。 此次发布会上，悦鲜活重磅发布全面升级的"四维进阶全链锁鲜"技术创新成果，即源头选鲜、瞬时锁 鲜、去杂凝鲜、隔氧储鲜全产业链锁鲜体系，从而实现更好保留牛奶的醇正鲜甜，实现更多活性营养、 更好口感的全面升级。 持续的技术创新正在转化为深度的市场穿透力。悦鲜活经过严格的多层级检测与监管 ...

Core Viewpoint - Anjiu Food Group Co., Ltd. has received approval from the China Securities Regulatory Commission for the issuance of up to 59,521,400 overseas listed ordinary shares, marking a significant step in the company's internationalization strategy [2] Group 1: Company Overview - Anjiu Food is a leading player in China's frozen food industry, holding a 6.2% market share in 2023, making it the industry leader [3] - The company has a market share of 12.7% in the frozen prepared food segment, which is four times that of the second-place competitor, and leads the frozen dish products market with a 4.9% share, surpassing the combined share of the second to fourth competitors [3] Group 2: Competitive Advantages - The company has established a comprehensive multi-channel sales network with over 2,000 distributors, covering traditional distribution, supermarkets, catering, and e-commerce [4] - Anjiu Food offers a diverse product matrix with over 400 SKUs across four main categories: frozen fish products, frozen meat products, frozen noodle and rice products, and frozen dish products [4] - The company has a strong focus on research and development, possessing a national-level enterprise technology center and holding 150 international management system certifications [4] Group 3: Strategic Significance of H-Share Listing - The H-share listing will provide multiple development opportunities, including expanding international financing channels and optimizing the capital structure [5] - It will enhance the company's international brand influence and support overseas market expansion [5] - The listing is expected to attract international strategic investors, improving corporate governance and laying the groundwork for future cross-border mergers and acquisitions [5] Group 4: Future Outlook - The frozen food industry is anticipated to experience broader growth due to ongoing consumption upgrades and the trend of restaurant chain expansion [6] - Anjiu Food aims to leverage its comprehensive product matrix, strong R&D capabilities, and extensive sales network to further enhance its leading position as industry concentration increases [6]

Core Viewpoint - Anjiu Food is accelerating its international expansion and has received approval for overseas listing, aiming to enhance its global presence and competitiveness [2][3]. Group 1: International Expansion Strategy - Anjiu Food plans to issue up to 59.52 million shares for overseas listing on the Hong Kong Stock Exchange, with a focus on expanding into high-growth international markets [2][3]. - The company aims to build a global supply chain platform to optimize costs and ensure a stable supply of quality raw materials such as fish paste and shrimp [2][8]. - The overseas revenue is projected to reach 168 million yuan in 2024, representing a year-on-year growth of 30.76%, becoming a new growth point for the company [2][8]. Group 2: Financial Performance - Anjiu Food's revenue for 2022, 2023, and 2024 was 12.183 billion yuan, 14.045 billion yuan, and 15.127 billion yuan, with year-on-year growth rates of 31.39%, 15.29%, and 7.70% respectively [5]. - The net profit for the same years was 1.101 billion yuan, 1.478 billion yuan, and 1.485 billion yuan, with growth rates of 61.37%, 34.24%, and 0.46% respectively, indicating a slowdown in growth [5]. - In Q1 2025, the company reported a revenue of 3.6 billion yuan, a decline of 4.13% year-on-year, and a net profit of 395 million yuan, down 10.01% year-on-year [6]. Group 3: Market Development and Partnerships - Anjiu Food is enhancing its distribution network by empowering distributors and collaborating with chain restaurants to develop customized products [4]. - The company plans to expand its sales coverage in overseas markets through brand building and marketing activities, targeting local supermarkets and restaurants [4]. - As of 2024, Anjiu Food has 249 overseas distributors, a year-on-year increase of 10.18%, reflecting its growing international footprint [8].

著名经济学家宋清辉在接受《中国能源报》记者采访时指出，"赴港上市的核心是国际化战 略本身。因此储能企业不管是在上市前或上市后，都需要有清晰、可执行的海外市场进入策 略、渠道建设方案以及风险控制措施等。建议拟赴港上市的储能企业组建或委托专业的团 队，负责与全球投资者进行有效沟通，解答疑问，传递公司价值。并且，当前国际投资者越 来越关注企业的环境、社会和公司治理（ESG）表现，储能企业应系统梳理和提升自身的 ESG实践，并进行有效披露。 众多企业的首选 自2023年下半年起，A股市场IPO上市审查政策收紧，使得包括储能相关企业在内的众多企业上市难度 激增。在此背景下，港股市场凭借其相对宽松的上市条件和国际化平台，成为众多企业的首选。瑞银证 券预计，2025年将有逾30家A股公司赴港上市，其中大部分是大型A股公司，涵盖各行各业。 今年以来，除南都电源外，包括中伟股份、海辰储能、宁德时代在内的多家储能领域企业也在谋划赴港 上市。例如，中伟股份日前公告称，公司已于4月22日递交在香港联交所主板挂牌上市的申请，并于同 日在香港联交所网站上刊登本次发行并上市的申请资料。该申请资料为公司按照香港证监会及香港联交 所的要求编制 ...

Core Viewpoint - The annual shareholder meeting of Kweichow Moutai is set to discuss various important reports and proposals, with a significant turnout of over 1,700 shareholders expected, indicating strong interest in the company's performance and future plans [1][2]. Group 1: Shareholder Meeting Highlights - The meeting will review the 2024 Board of Directors' report, Supervisory Board report, annual report, and profit distribution plan [1]. - The venue was changed to accommodate the larger-than-expected number of attendees, reflecting the high level of shareholder engagement [1]. - Shareholders are particularly interested in potential price increases for Feitian Moutai, direct sales ratios, and product diversification [2][3]. Group 2: Financial Performance and Goals - Kweichow Moutai reported a total revenue of 174.14 billion yuan for 2024, a year-on-year increase of 15.66%, and a net profit of 86.23 billion yuan, up 15.38% [3]. - The company aims for a revenue growth target of approximately 9% for 2025, raising questions among shareholders about the rationale behind this conservative target [3]. - Cumulative cash dividends since the company's listing in 2001 have reached 301.44 billion yuan, with a dividend payout ratio of 59.52% [2]. Group 3: International Expansion - Kweichow Moutai is accelerating its international strategy, with overseas market revenue reaching 1.12 billion yuan in the first quarter, a 37% increase year-on-year [3]. - Shareholders are keen to learn about new plans for expanding into international markets [4].

重要提示 如 闊下對本招股章程之任何內容有任何疑問,應尋求獨立專業意見。 Contemporary Amperex Technology Co., Limited 寧德時代新能源科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 全球發售 | 全球發售項下的發售股份數目 : 117,894,500股H股(視乎發售量調整權 | | --- | | 及超額配股權行使與否而定) | | 香港發售股份數目 : 8.842.100股H股(可予車新分配及視乎 | | 發售量調整權行使與否而定) | | 國際發售股份數目 : 109.052.400股H股(可予重新分配及視 | | 乎發售量調整權及超額配股權行使與 | | 否而定) | | 最高發售價 : 每股H股263.00港元,另加1.0%經 | | 紀佣金、0.0027％證監會交易徵 | | 費 · 0.00015% 會財局交易徵費及 | | 0.00565% 聯交所交易費(申請時以港 | | 元全額繳足) | | 商值 . 每股H股人民幣1.00元 | 股份代號 : 3750 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 (按英文 ...